Company ProfilePremium

Aptamer Sciences Inc.

Company Profile Analysis

Ticker: 291650.KQ주식회사 츌립앤사이언스

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aptamer Sciences Inc. - Company showcase

Year Founded & Workforce

2011

38 Employees

Aptamer Sciences Inc. logo

Aptamer Sciences Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aptamer Sciences Inc. Overview

CHOOLIP & SCIENCES is a micro-cap KOSDAQ company in transition. It was founded in 2011 as Aptamer Sciences, a POSTECH spin-off built around proprietary SELEX aptamer discovery. For most of its history it was a pre-revenue platform biotech: it commercialized one approved diagnostic (the AptoDetect™-Lung blood test, MFDS Class 3, 2017), and in 2024 it took its lead therapeutic, AST-201, a GPC3-targeted aptamer-drug conjugate (ApDC™), into a Phase 1 trial. KOSDAQ listing-maintenance thresholds for revenue and pre-tax losses forced a sequence of defensive measures. These included absorbing a bioanalytical CRO (ISS) in 2024, raising equity repeatedly, and handing control to Altcast in 2025. In 2026, new management bought a US premium pet-treat brand (Choolip Inc., US$11.4M) and renamed the company after it. Today the company combines an early-clinical oncology platform (AST-201 with an MSD Keytruda supply agreement; Trop2-ApDC preclinical) with CRO, oligo-synthesis and consumer pet-nutrition revenue lines. Value depends heavily on capital-markets access.


Company's own description

In its corporate materials, the company describes itself as an R&D-driven biotech commercializing aptamer technology platforms for innovative therapeutic and diagnostic products. It positions itself as able to generate high-affinity, high-specificity aptamers, optimize them, and develop new therapeutic and diagnostic modalities from them (Scientist.com / Informa Asia TIDES exhibitor profile). Its 2024 English press release describes it as a KOSDAQ-listed leader in the aptamer field with an integrated platform, branded ApDC™ (Aptamer Drug Conjugate), focused on oncology pipelines (PR Newswire, 25 March 2024). Filing-aggregator summaries of the FY2025 annual report describe a clinical-stage biopharmaceutical company whose development pipeline also includes Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS) (FinancialFilings.com).

When the name changed, the company said in public statements that it would keep both the drug-development and CRO businesses, and would use distribution of healthcare and lifestyle products as an additional revenue base (Dealsite, 6 July 2026).

Independent characterization

The company is best described as a hybrid micro-cap with four economically distinct activities:

  1. Aptamer therapeutics (core value driver, pre-revenue). The ApDC platform links a target-specific DNA/RNA aptamer to a cytotoxic or functional payload. The lead asset, AST-201, embeds gemcitabine within the sequence of a GPC3-binding aptamer. A Trop2-targeted ApDC (AST-203a) and an ApDC immuno-oncology candidate (AST-202) follow. The monetization model is out-licensing (technology transfer) and co-development; no license deal on a therapeutic asset has been publicly announced to date.

  2. Diagnostics. AptoDetect™-Lung is a blood-based multi-protein (7-marker) aptamer assay that produces a lung-cancer risk score. It is sold in Korea through non-reimbursed (self-pay) hospital channels and, from 2023, through health-screening providers. Revenue has historically been very small.

  3. Services (CRO / bioanalysis / oligo synthesis / custom aptamer discovery / reagent distribution). This line came mostly from the 2024 absorption of International Scientific Standard Inc. (ISS), a bioanalytical CRO, plus oligonucleotide synthesis and custom aptamer discovery contracts (e.g., a KRW 417M aptamer-discovery contract in September 2025). It provides recurring, contract-based revenue and helped the company meet KOSDAQ's KRW 3bn revenue threshold in FY2025.

  4. Consumer pet nutrition (from March 2026). Choolip Inc. is a US (California) premium pet-treat and beverage brand. It sells mainly on Amazon and its own website, with products manufactured in Korea.

Revenue model mix (latest, FY2025). Mostly services (CRO, synthesis, discovery contracts) plus small diagnostic product sales. There is no licensing income. From FY2026, consolidated revenue should be dominated by consumer product sales via Choolip. Segment proportions are not publicly disclosed.

Value-chain position. The company sits at the discovery and early-clinical stage in therapeutics, relies on CDMOs for GMP manufacturing (a 2022 CDMO agreement with China's Asymchem for AST-201 was reported by Daum/News1, July 2024), and acts as a service provider in bioanalysis. In pet nutrition it is a brand owner with contract manufacturing in Korea.

Customer types and end-markets. Global and Korean pharma/biotech (licensing targets, CRO clients, custom-aptamer clients); Korean tertiary hospitals and health-screening centers (diagnostics); US pet owners via e-commerce and retail (pet nutrition).

Strategy

Stated strategic themes (paraphrased from company statements)

  1. Platform value via out-licensing. Prove the ApDC platform clinically through AST-201, then secure technology transfer or co-development. The goal has been repeated since 2021, with targets of "within the year or H1 next year" stated in July 2024 (News1). No license had been announced as of October 2026.

  2. Combination positioning in HCC. Move AST-201 from monotherapy Phase 1 into a company-sponsored Phase 2 combination with pembrolizumab under the April 2026 MSD supply agreement. Management describes this as a strategic turning point.

  3. Early preclinical licensing of Trop2-ApDC (AST-203a). Leverage big-pharma interest in Trop2 to seek licensing before the clinic (Asia Economy, Jun 2026).

  4. Cash-cow diversification. Build revenue through CRO and oligo services (2024–2025), then consumer healthcare and lifestyle distribution (Choolip; goods, character merchandise and e-commerce added to corporate objects in July 2026). The stated aim is to fund drug development and keep the listing in compliance.

  5. Listing compliance. Keep the pre-tax-loss ratio below 50% of equity and revenue at KRW 3bn or more.

Initiatives in the last 24 months

InitiativeDateDetail
ISS mergerJun–Aug 2024Revenue base plus in-house bioanalysis for ApDC programs
Rights offeringAug–Nov 2024≈KRW 20bn; to improve the financial structure and fund AST-201
Kolon Pharma pancreatic cancer co-developmentOct 2024Joint development and global licensing
Altcast control transfer and funding packageSep–Oct 2025≈KRW 30bn total including the CB; uses stated as working capital and acquisition of other companies' securities
Wellnew & Co. placementJan–Mar 2026KRW 12bn; earmarked for distribution-business investment (KRW 5bn in 2026, KRW 7bn in 2027)
Choolip acquisitionMar 2026Entry into US pet healthcare
MSD CTCSAApr 2026AST-201 + Keytruda Phase 2 in HCC
KRW 8bn placementApr 2026Working capital (details not disclosed)
Trop2-ApDC national grantJun 20262-year lead optimization and non-clinical work
Share consolidation 2:1Jun–2026 (trading halt from a "22nd" date)Par KRW 500 → 1,000
Name change and new corporate objectsJul 2026Goods/souvenirs, character products, e-commerce
AST-201 US patentAug 2026Global IP for licensing

ESG commitments and cost programs: none disclosed. Medium-term financial targets / guidance: none published. Historical IPO-era projections were not met (Dealsite, Aug 2022).

Products & Services

Therapeutics pipeline

AssetModality / targetPayload / mechanismIndicationsStage (latest)Key facts
AST-201 (also BiFAp-GPC3)ApDC; Glypican-3 (GPC3)Gemcitabine incorporated into the aptamer DNA sequenceGPC3+ advanced solid tumors; HCC and NSCLCPhase 1a/1b (Korea), NCT06687941IND filed 12 Mar 2024, approved Oct 2024. Sites: Bundang CHA, Samsung Medical Center, Severance, National Cancer Center; lead investigator Prof. Hong-jae Chon (Bundang CHA). Dosing IV on days 1, 8 and 15 of 28-day cycles. Phase 1a sets MTD/RP2D; Phase 1b expands in GPC3+ tumor types.
AST-201 + pembrolizumabCombinationAnti-PD-1 synergyHepatocellular carcinomaPhase 2 planned (company-sponsored); MSD supplies Keytruda under a CTCSA signed 15 Apr 2026MSD provides drug supply and scientific collaboration (Kukinews; Asia Economy)
AST-203a (Trop2-ApDC)ApDC; Trop2—Solid tumorsLead optimization / non-clinical; national grant (2 years) from Jun 2026Company aims for early licensing at the preclinical stage (Asia Economy, 18 Jun 2026)
AST-202ApDC immuno-oncology; binds cancer cells and regulatory T cells (CD25 listed as a target keyword by THE VC)—Solid tumors (IO)Preclinical; AACR and SITC 2023 dataMedigate News, May 2024
Pancreatic cancer program——Pancreatic cancerCo-development with Kolon Pharmaceutical (Oct 2024)Detailed terms not publicly disclosed
ApRC platformAptamer-radioligand conjugateRadionuclideHemato-oncology / othersDiscoveryFinancialFilings summary of FY2025 annual report
ApIS platformAptamer-immune stimulator conjugateImmune agonistOncologyDiscoverySame
BBB shuttle aptamerBiFAp-based transcytosis shuttleCarries antibodies, peptides, siRNA across the blood-brain barrierCNS diseasesPreclinical; MTAs with several large pharma reportedBioSpectator (2020); Medigate (2021, 2024)
AlloMAp insulin receptor agonist/sensitizerAllosteric modulator aptamerInsulin receptorDiabetesPreclinical (historical; current status not disclosed)CDAs with 6 global pharma reported at IPO (BioSpectator, Aug 2020)
Chimeric aptamer / aptamer-siRNABifunctional aptamer-siRNAsiRNA deliveryOncologyCo-development pact with Curigin (company history lists "June"; year not confirmed)Saramin company history
COVID-19 neutralizing aptamerNeutralizing aptamerSpike bindingCOVID-19Non-clinical grant (2021); current status not disclosedDealsite, Jul 2021

Preclinical claims for AST-201 (company-reported). Better efficacy than sorafenib in animal models, and synergy with anti-PD-1 therapy (Patsnap Synapse, citing the company's March 2024 release). The company states that the human-equivalent gemcitabine dose in AST-201 is about 30–40 mg/m², compared with 1,000 mg/m² for free gemcitabine (Daum/News1, July 2024). Management estimates that over 70% of HCC patients are GPC3-positive and that about 40% of all HCC patients form the target population. The planned path is entry as a second-line therapy with a partner, then expansion into first-line-resistant GPC3+ patients (eToday, Oct 2024). Composition patents: Korea, China and Japan (pre-2024), and the United States (registered August 2026).

Diagnostics

ProductDescriptionRegulatoryTarget customerPricingNotes
AptoDetect™-LungBlood test measuring 7 serum proteins with aptamers; an algorithm generates a lung-cancer risk score; positioned as a complement to LDCTMFDS Class 3, Sep 2017Tertiary hospitals (Asan Medical Center and Kyung Hee University Hospital named as customers); health-screening centers (from 2023)Non-reimbursed (self-pay); price not disclosedCapacity ≈300,000 tests/year (2023). China sales targeted from 2021 at IPO, but not evidenced. A US LDT route via a domestic partner with a CLIA lab was reported as under preparation in 2024. An India entry was reported in an undated 2026 headline.
Pancreatic and liver cancer diagnostic kitsPipeline at IPO (approval was targeted for 2022)Not approved per sources reviewed——Status not disclosed
COVID-19 aptamer antigen testPipeline at IPO (2020)———Status not disclosed

Services

ServiceDescriptionOriginNotes
Bioanalytical CRONon-clinical and clinical sample bioanalysis (peptides, oligos, biologics)ISS, founded 2008 as a JV of Battelle Memorial Institute and Yuyu Pharma; merged Aug 2024ISS was described as generating KRW 3–5bn of annual revenue (company statement to IB Tomato, Oct 2024); price ≤KRW 2bn
Oligonucleotide synthesisCustom oligo synthesisIn-housePart of ≈KRW 0.6bn Q1 2025 revenue
Custom aptamer discoverySELEX discovery and optimization for partnersIn-house platformExample: KRW 417M contract with a domestic targeted-oncology developer, 26 Sep 2025
Research reagent / sample distributionDistribution of clinical-analysis and research reagents and samplesExpanded 2025Money Today, Jul 2025

Consumer / pet nutrition (Choolip Inc., USA)

ProductDescriptionLaunchChannelNotes
Squeeze Vita StickCreamy paste-type pet treat with 30+ vitamins and nutrients; seven organ-targeted variants (joints, kidney, heart, eyes, skin, liver, brain)Oct 2023 (first products on Amazon and own site)Amazon, own e-commerce; Costco referenced in media headlineAmazon's Choice within two months of launch (company claim)
Berry Good MilkLactose-free vitamin-fortified pet beverage made with Korean grade-1A raw milk—SameWon first place in the cat category of the SuperZoo 2024 new product showcase

Choolip's 2025 Amazon sales were 94,789 units, with annual order value of US$2,828,360 (Money Today, 26 Mar 2026, citing the company). All products are manufactured in Korea (HiNews, Sep 2026). There is a discrepancy: the founding date is reported as January 2024 (Montrose, California), while the first product launch is reported as October 2023. The brand may have predated incorporation of the acquired US entity.

Financial Narrative

Basis: Separate (non-consolidated) K-IFRS statements, KRW bn. DART statements were not directly accessed. Figures come from disclosure-derived media reports and aggregators. Blank cells are not publicly verified.

Income statement: notes and sources

Sources: FY2022–FY2023 net losses from IB Tomato (21 Oct 2024). FY2024 from DigitalToday (citing the FY2024 audit). FY2025 from FinancialFilings (FY2025 annual report filed 13 Mar 2026). Revenue never exceeded KRW 1bn from listing (FY2020: KRW 0.229bn) through FY2023 (IB Tomato). Dealsite (Sep 2024) described annual revenue of roughly KRW 0.2–0.3bn before the ISS merger. No dividends were found in any reviewed source; this is consistent with continuous losses.

Pre-window reference: notes and sources

Source: Kiwoom company reports (Dec 2020, Jun 2021, Oct 2021). FY2020 revenue and net loss are from IB Tomato.

Margins (computed)

Revenue CAGR over FY2021–FY2025 is not computable from verified data, and gross and EBITDA margins are not disclosed.

Balance sheet

FY2025 liabilities are derived (assets minus equity). Current ratios are from THE VC. Cash, total debt (short/long split), goodwill and intangibles, and working capital are not publicly verified. FY2020 reference (Kiwoom): current assets KRW 35.3bn, total liabilities KRW 1.7bn, BPS KRW 4,046.

Ratios (computed where possible)

ROIC, net debt/EBITDA, interest coverage and the cash conversion cycle are not meaningful (negative EBITDA) or not disclosed.

Commentary

Trend. The company has never been profitable. Net losses widened from about KRW 3.8bn (FY2020) to KRW 7.1bn (FY2022) and a peak of KRW 13.6bn (FY2023). The FY2023 peak likely reflected pre-clinical and IND-enabling spending plus possible impairments (composition not disclosed). Losses then eased to KRW 8.7bn (FY2024) and KRW 8.6bn (FY2025). Annual cash burn of about KRW 9–10bn (FY2025 operating cash outflow KRW 9.67bn) against equity in the high-20s KRW bn implies a short self-funded runway without fresh capital, and the company has in fact raised equity or CBs in every year since 2024.

Inflection 1 — KOSDAQ maintenance pressure (2023–2025). As a technology-special listing, the company lost its grace period from the pre-tax-loss test in 2023 and from the KRW 3bn minimum revenue test in 2025 (Dealsite, Jul 2026). It responded in three ways. It boosted equity through the 2024 rights offering and asset revaluation, which brought the pre-tax-loss-to-equity ratio to about 34%, below the 50% limit (Dealsite, Jul 2026). It acquired revenue by merging in ISS. And it pursued contract services. FY2025 revenue of KRW 3.50bn cleared the KRW 3bn threshold by a thin margin.

Inflection 2 — Change of control and capital injection (H2 2025). Altcast-led placements (KRW 20bn announced) and a KRW 10bn CB raised assets from KRW 32.0bn to KRW 41.1bn. Liabilities roughly doubled to about KRW 12.9bn, consistent with the CB being booked as debt. Equity rose only KRW 2.8bn despite announced placements of KRW 20bn and a KRW 8.6bn loss. Analyst inference: not all announced placement proceeds appear to have been received by 31 Dec 2025, or other equity movements offset them; reconcile with the FY2025 statement of changes in equity.

Inflection 3 — Pet-nutrition consolidation (FY2026). Choolip's reported 2025 Amazon order value of about US$2.8M (≈KRW 4bn) is larger than the parent's entire FY2025 revenue. From Q2 2026, consolidated revenue should step up materially, gross margin will reflect consumer-goods economics, and goodwill and intangibles from a KRW 17.2bn purchase price will appear on the balance sheet.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Lines

Business lineContentsProducts / servicesStatus

Drug development (ApDC and platforms)

GPC3, Trop2, Treg/CD25 programs; ApRC, ApIS, BBB shuttle, AlloMAp, BiFAp

AST-201, AST-202, AST-203a; legacy diabetes and CNS programs

Clinical (Ph1) and preclinical; no revenue

Diagnostics

Aptamer multiplex blood tests

AptoDetect™-Lung

Approved in Korea (2017); small sales

Services

Bioanalytical CRO (ex-ISS), oligo synthesis, custom aptamer discovery, research reagent/sample distribution

Contract services

Revenue-generating since H2 2024

Consumer / pet nutrition (from Mar 2026)

Choolip Inc. (USA)

Squeeze Vita Stick, Berry Good Milk

Revenue-generating; consolidation from Q2 2026

Goods / character / e-commerce (planned)

Added to corporate objects July 2026

Not yet disclosed

Planned

Business Lines (Annual)

Business line (KRW Bn)FY2024FY2025

Total revenue (KRW Bn)

1.083.50

Drug development / licensing (KRW Bn)

00

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

———1.083.50

Operating income (KRW Bn)

———-7.10—

Net income (KRW Bn)

—-7.10-13.60-8.70-8.62

Dividends per share (KRW)

00000

Income Statement and Per-Share Data

MetricFY2016FY2017FY2018FY2019FY2020

Revenue (KRW Bn)

0.10.20.30.40.23

Operating income (KRW Bn)

-1.4-1.9-3.4-3.3—

Net income (KRW Bn)

-1.4-1.9-7.3-3.9-3.8

EPS (KRW)

-598-647-2,252-631—

Margin Analysis (%)

MetricFY2024FY2025

Operating margin (%)

-657.4—

Net margin (%)

-805.6-246.3

Revenue growth YoY (%)

—224.1

Balance Sheet and Margin Analysis (%)

MetricFY2023FY2024FY2025

Total assets (KRW Bn)

—32.041.11

Total liabilities (KRW Bn)

—6.512.88

Total equity (KRW Bn)

—25.428.23

Paid-in capital (KRW Bn)

——20.58

Current ratio (%)

164.3483.6224.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

————-9.67

Dividends paid (KRW Bn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2024FY2025

ROE on year-end equity (%)

-34.3-30.5

ROA on year-end assets (%)

-27.2-21.0

Total liabilities to equity (x)

0.260.46

Asset turnover (x)

0.030.09

Share Price History

DatePrice / data pointSource

52 weeks to Dec 2020

High KRW 32,750 / low KRW 19,800

Kiwoom

1 Dec 2020

KRW 24,600; market cap KRW 208.3bn

Kiwoom

30 Jun 2021

KRW 21,550; market cap KRW 182.4bn

Kiwoom

21 Oct 2021

KRW 19,700; market cap KRW 166.8bn

Kiwoom

Sep 2023

≈KRW 955 (shown in the Money Today ticker; quote time unclear)

Money Today

26 Sep 2025

KRW 1,010

DigitalToday

27 Oct 2025

KRW 1,067

DigitalToday

Jan 2026

Reference price KRW 1,107 (placement pricing)

Dealsite

26 Mar 2026

≈KRW 690–721 (tickers at different times)

Money Today

16 Jul 2026

KRW 941 (close)

Asia Economy ticker

Share Count (millions)

MetricFY2021FY2025

Shares outstanding (millions)

8.46640.257

Valuation Multiples

MultipleCHOOLIP & SCIENCESNote

EV/Sales (FY2025)

≈17x (computed: ≈KRW 60.7bn market cap ÷ KRW 3.50bn revenue, ignoring net cash or debt)

—

P/B (FY2025)

≈2.2x (computed: KRW 60.7bn ÷ KRW 28.23bn equity)

Gurufocus showed 4.95x at an earlier, unspecified date

Analyst Conclusions

Management guidance

No quantitative financial guidance has been published. Qualitative priorities:

  1. Advance AST-201 monotherapy Phase 1 and start the MSD-supported Keytruda combination Phase 2 in HCC.

  2. Optimize the Trop2-ApDC lead and seek preclinical licensing.

  3. Pursue global licensing and co-development of AST-201 using the US patent.

  4. Maintain the CRO business and expand healthcare and lifestyle distribution through Choolip to stabilize cash flow.

Consensus expectations

There is no sell-side consensus.

Bull case

  1. Clinical validation plus licensing. The MSD supply agreement and the US patent make AST-201 a more credible licensing asset. A positive signal from Phase 1 or the early combination study in GPC3+ HCC could trigger a China-focused license, which is the company's stated priority market.

  2. Revenue step-change. Choolip's 2025 Amazon order value (about US$2.83M) already exceeds parent revenue. Consolidation could lift FY2026 revenue several-fold and sharply reduce listing-maintenance risk.

  3. Capitalized ownership. Two strategic holders (the Altcast group and Wellnew & Co.) have injected about KRW 40bn since Sept 2025, with one-year lock-ups. That signals continued sponsor support for funding.

Bear case

  1. Platform without proof. After more than 10 years and multiple deal-timing promises, no therapeutic license exists. ApDC human efficacy is unproven, and the HCC standard of care is strong.

  2. Dilution machine. Equity has been raised every year, and a KRW 10bn CB overhang remains.

  3. Identity drift. Renaming the company after a pet-treat brand, adding goods and character-merchandise objects, and a shrinking R&D headcount point to declining capital and attention for drug development.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
AST-201 Phase 1 safety/efficacy data (MTD/RP2D)Next congress cycle (not dated)Gate for Phase 2 and licensing
First patient dosed in the AST-201 + Keytruda Phase 22026–2027Execution of the MSD collaboration
Q3 2026 quarterly report (consolidated)Mid-Nov 2026First clear view of Choolip revenue, margins and goodwill
FY2026 annual reportMar 2027Listing-test compliance; impairment testing
Any AST-201 or Trop2 licensing announcementUnspecifiedCore value-realization event
CB conversions and new placementsOngoingDilution
Clarification or disclosure of the AriBio and India headlinesOngoingSeparates rumor from fact
KRX surveillance status (investment warning, possible trading halt)Near termTrading risk
Executive and R&D headcount trendsOngoingCapacity to execute the pipeline

Concluding analyst verdict

CHOOLIP & SCIENCES is no longer the pure-play aptamer biotech that listed on KOSDAQ in 2020 as Aptamer Sciences. The scientific core is real. The company has proprietary SELEX discovery, an approved aptamer diagnostic, and a first-in-class GPC3-targeted ApDC (AST-201) now in a multi-center Korean Phase 1. That asset has composition IP across the four most important jurisdictions and a Keytruda supply agreement with MSD for a combination study in liver cancer. These are credible assets for a company of this size, and the Trop2-ApDC grant adds a second licensing option in a target class big pharma values.

The financial record, however, dominates the investment case. Revenue stayed below KRW 1bn for most of its listed life. Losses have run at KRW 7–14bn a year. Every year since 2024 has required new equity or convertible debt simply to fund operations and keep the listing compliant. The 2025 sale of control to Altcast, the 2026 placements, the Choolip acquisition and the rename show that the new sponsors are optimizing for listing durability and near-term revenue rather than a focused drug-development strategy.

The investment case is therefore binary and event-driven. A clinical readout or licensing deal for AST-201 or the Trop2 program could revalue the platform well above the current market capitalization. Without one, the company's value rests on a small consumer pet-nutrition business and a CRO, with continuing dilution. Investors and corporate counterparties should focus on three things: AST-201 Phase 1 data and Phase 2 initiation, the first consolidated quarters showing Choolip's real contribution and margins, and the cadence of further equity issuance. Absent licensing evidence, we regard the stock as a high-risk, speculative micro-cap whose biotech optionality is real but under-resourced.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundSource

Jib-hoon Jung (정집훈)

CEO and inside director

CEO from 27 Oct 2025

Born 10 Jul 1972. Concurrently CEO of Altcast (KOSDAQ) since 21 Jan 2025 and CEO of Benoti&R (베노티앤알) since 29 Mar 2019, which the filing lists as KOSDAQ-listed. Held no shares personally at appointment.

DigitalToday (CEO change disclosure)

Dong-il Han (한동일)

Co-founder; CEO 2011 – Oct 2025

≈14 years

Led POSCO's aptamer business planning from 2005; sold his controlling stake to Altcast in Sept 2025

BioSpectator; Dealsite

Young-ki Yoon (윤영기)

Executive Director (전무)

Named as filing officer in the FY2021 report

—

FY2021 annual report

Kwang-yong Lee (이광용)

Executive Director / CBO

Cited 2024

—

Medigate News, May 2024

Jung-eun Choi (최정은)

Executive Director, clinical development

Joined ≈2023

Pharmacy BS/MS/PhD, Ewha Womans University; prior clinical development roles at Boryung, JW Pharmaceutical, Kainos Medicine

BioSpectator

Dae-kyun Lee (이대견)

Head of Drug Discovery Research Institute

Cited 2022

—

Newsis, Feb 2022

Ki-seok Kim (김기석)

Head of Research Institute (earlier era)

——

BioSpectator

Major Shareholders

HolderShares / stakeDateSource

Altcast Inc. and related parties (incl. Daehyun Gigun; Lamicus, the largest shareholder of Altcast's largest shareholder)

13,665,891 shares (33.95%)

End Q3 2025

Dealsite, Jan 2026

Altcast group (pro forma after Wellnew placement)

≈26.1%

Mar 2026

Dealsite, Jan 2026

Wellnew & Co. (웰뉴앤코)

12,000,000 shares (22.9% post-issue)

Mar 2026

Dealsite, Jan 2026

Sunbox, Hoonis

KRW 2.5bn each of the Sept 2025 placements

Oct–Nov 2025

Dealsite, Sep 2025

KP Investment; OU Investment

CB holders (KRW 7bn and KRW 3bn; conversion price KRW 1,230 before consolidation)

Sep 2025

Dealsite

April 2026 placement investor(s)

KRW 8bn (identity not disclosed in sources reviewed)

Apr 2026

JobKorea

Former founder group (Han + 5 related parties)

32.7%

2020–2021

Kiwoom

Competitive Landscape

Competitors by Segment

Business lineCompetitorTypeRelevance

Aptamer platforms

Aptamer Group plc (UK, AIM)

Aptamer discovery services and diagnostics

Direct platform/services peer

Aptamer platforms

SomaLogic (part of Standard BioTools, USA)

Aptamer (SOMAmer) proteomics

Platform heritage; proteomics diagnostics

Aptamer platforms

Base Pair Biotechnologies (USA)

Custom aptamer development

Services peer

Aptamer therapeutics

Astellas (Izervay, via Iveric Bio)

Approved aptamer drug (2023)

Validates the modality; different therapeutic area

ADC / Trop2

Gilead Sciences (Trodelvy)

Approved Trop2 ADC

Benchmark for AST-203a

ADC / Trop2

AstraZeneca / Daiichi Sankyo (Datroway, Trop2 ADC)

Approved Trop2 ADC

Benchmark for AST-203a

ADC platforms (Korea)

LigaChem Biosciences (KOSDAQ)

ADC linker/payload platform with global licenses

Competes for licensing attention

HCC therapy

Roche (atezolizumab + bevacizumab); AstraZeneca (durvalumab + tremelimumab)

Standard-of-care first-line HCC

Defines the bar for AST-201 combinations

GPC3-targeted therapy

CARsgen (GPC3 CAR-T); Chugai/Roche (historical GPC3 antibody)

GPC3 programs

Target-level competitors

Lung cancer blood tests

Protan Bio; Genecurix; Xenohelix (Korea); Biodesix (USA, Nodify); DELFI Diagnostics (USA)

Proteomic/fragmentomic tests

Direct diagnostic competitors (THE VC peer set for Korea)

Bioanalytical CRO (Korea)

Bio Toxtech; Dt&CRO; other domestic bioanalysis labs

Non-clinical CRO

Services competitors

Pet treats / supplements (USA)

Inaba (CIAO Churu lickable puree); Mars (Temptations, Greenies); Nestlé Purina; Zesty Paws (H&H Group)

Pet treats and supplements

Direct category competitors for Squeeze Vita Stick

Competitor Detail

MetricCHOOLIP & SCIENCES

Revenue

KRW 3.50bn (FY2025)

Growth

+224% FY2025 (computed)

Net margin

−246% (FY2025, computed)

Lead asset stage

Phase 1 (AST-201)

Company Snapshot

$2.5M

Revenue

38

Employees

2011

Founded

Seongnam, South Korea

Headquarters

SWOT Analysis

Strengths

  • Clinical-stage lead asset. AST-201 Phase 1 was authorized by MFDS in Oct 2024 at four top Korean cancer centers (NCT06687941).
  • Global composition IP. The US patent was registered in Aug 2026, adding to Korean, Chinese and Japanese patents.
  • Big-pharma clinical collaboration. The MSD CTCSA (15 Apr 2026) supplies Keytruda for a company-sponsored Phase 2 combination.
  • Non-dilutive validation. The Trop2-ApDC national program grant (Jun 2026) and 11 national R&D projects recorded (THE VC).
  • Revenue diversification achieved. FY2025 revenue reached KRW 3.50bn, up from KRW 1.08bn, clearing the KRW 3bn KOSDAQ threshold.
  • Approved diagnostic product. AptoDetect-Lung has MFDS Class 3 approval (2017) and capacity of about 300,000 tests per year.

Weaknesses

  • Persistent losses. Net losses of KRW 7.1bn, 13.6bn, 8.7bn and 8.6bn over FY2022–FY2025.
  • Cash burn. FY2025 operating cash outflow was KRW 9.67bn against equity of KRW 28.2bn.
  • No licensing deal despite out-licensing being the core model since 2020 and stated deal targets (e.g., "within 2024 or H1 2025", July 2024).
  • Missed IPO-era targets. Diagnostic sales in China from 2021 and pancreatic/liver kits by 2023 did not materialize (Dealsite, Aug 2022).
  • Shrinking organization. Headcount fell from 38 (June 2026) to 20–23 (Aug–Sep 2026); 11 departures in the year to Sep 2026.
  • Thin governance disclosure. No individual compensation disclosure, a small board, and a CEO serving concurrently as CEO of two other listed companies.

Opportunities

  • AST-201 + pembrolizumab Phase 2 data could re-rate the asset and support licensing, especially in China, the company's stated priority.
  • Trop2 licensing at the preclinical stage, given big-pharma interest the company cites.
  • Choolip scale-up. Its 2025 Amazon order value of about US$2.83M already exceeds the parent's FY2025 revenue. Costco and other retail channels have been referenced.
  • Aptamer market growth at a projected 20.3% CAGR to 2032 (FS Research).
  • Platform breadth (ApRC, ApIS, BBB shuttle, aptamer-siRNA) offers additional partnering options.
  • Group synergies with the Altcast group and Wellnew & Co. in distribution (the KRW 12bn placement is earmarked for distribution investment).

Threats

  • Dilution and overhang. Placements of KRW 20bn (2025), KRW 12bn and KRW 8bn (2026), plus a KRW 10bn CB with potential conversion of about 27.8% of 2025 shares.
  • Listing risk. Revenue and pre-tax-loss tests continue to apply annually. FY2025 revenue cleared the threshold by only KRW 0.5bn.
  • Clinical risk. ApDC efficacy in humans is unproven, and the HCC standard of care is strong.
  • Strategic drift. Media have flagged concern that the Choolip-centric identity may weaken drug-development momentum (Dealsite, Jul 2026).
  • FX and consumer-market exposure via a US-dollar subsidiary, against large incumbents (Inaba, Mars, Nestlé Purina).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Q1 2025 (reported Jul 2025)About KRW 0.6bn of quarterly revenue from oligo synthesis and CRO analysisShows the run-rate needed for the KRW 3bn test
7 Jul 2025Company denies M&A/sale reports; says it is open to strategic investment proposals; says AST-201 Phase 1 is progressing quickly, with interim data targeted for Sept–Oct 2025Shares fell 8.2% on the day (Money Today). The control sale followed two months later.
9 Sep 2025SPA: Han Dong-il and 2 related parties sell ≈2.44M shares (≈27%) to Altcast for KRW 4.4bn (KRW 1,800/share)Change of control; founder exit
9 Sep 2025Two KRW 10bn third-party placements at KRW 1,078 (18.55M shares) to Altcast, Daehyun Gigun, Lamicus, Sunbox, HoonisHeavy dilution; locks in Altcast-group control
9 Sep 2025KRW 10bn 2nd private CB (conversion KRW 1,230; maturity Sep 2028) to KP Investment and OU InvestmentPotential ≈8.13M new shares (27.8% of then-outstanding)
26 Sep 2025KRW 417M aptamer discovery service contract with a domestic oncology developer (38.5% of FY2024 revenue)Services revenue toward FY2025 compliance
Sep–Oct 2025AST-201 interim Phase 1 data targeted for presentation at a congress (per Jul 2025 guidance)–
24 Oct 2025Scheduled payment date of the first KRW 10bn placementCash inflow
27 Oct 2025EGM elects Jib-hoon Jung; board appoints him CEO, replacing Han Dong-ilNew management under Altcast
27 Oct 2025Registered-director changes (multiple resignations and appointments)Board reconstitution
28 Nov 2025Scheduled payment date of the second KRW 10bn placement–
28 Jan 2026KRW 12bn placement to Wellnew & Co. at KRW 1,000 (9.7% discount); 12M shares; 22.9% stakeSecond large holder emerges; funds earmarked for distribution
5 Mar 2026Wellnew placement payment date; new shares listed 20 MarShares outstanding ≈52.26M (pre-consolidation)
13 Mar 2026FY2025 annual report: revenue KRW 3.50bn, net loss KRW 8.62bn, assets KRW 41.11bn, equity KRW 28.23bn, operating cash flow −KRW 9.67bnRevenue threshold met; continued losses
23 Mar 2026New registered officer appointment (registry)Governance change
25–26 Mar 2026Acquires Choolip Inc. (US$11.4M)Pivot into consumer pet healthcare
Apr 2026KRW 8bn third-party placementFurther dilution and capital
15 Apr 2026MSD clinical trial collaboration and supply agreement: AST-201 + Keytruda Phase 2 in HCCFirst big-pharma clinical collaboration (supply only, no economics)
Jun 2026Board approves 2:1 share consolidationCorrects a low share price
18 Jun 2026Trop2-ApDC (AST-203a) selected for a national new-drug development grant (2 years)Non-dilutive funding; Trop2 licensing narrative
3–6 Jul 2026Media report the company has escaped listing-risk designation (pre-tax-loss test met in 2024, revenue test in 2025)Compliance relief
8 Jul 2026EGM approves name change to CHOOLIP & SCIENCES and new consumer-goods objectsIdentity shift; investor concern about the biotech focus
2026 ("22nd", month not confirmed)KRX trading suspension for share consolidation (electronic registration change)Technical; adjusts price history
26 Aug 2026US composition-of-matter patent for AST-201Strengthens licensing package
Aug 2026Headcount 23 (THE VC)Lean organization
30 Sep 2026Media feature: Choolip keeps a "made in Korea" production policy for US salesBrand positioning
Late Sep 2026Listed among KRX "investment caution" / short-sale-related noticesSpeculative trading
≈11–12 Oct 2026KRX "investment warning" designation for 291650Signals an abnormal price rise; heightened volatility
Undated 2026Headlines: share price hit the daily upper limit on reports of (a) an AriBio acquisition push and (b) a lung-cancer kit entry into Indiatreat as rumor until confirmed by DART

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Total revenue rose from KRW 1,080 Mn in FY2024 to KRW 3,500 Mn in FY2025.
Aptamer Sciences Inc. — Revenue by Segment
Series (KRW Mn)FY2024FY2025
Total revenue1,0803,500

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.